Table 1 Characteristics of acute myeloid leukemia and myelodysplastic syndrome patients
Characteristic | AML N = 33 | MDS-EB1/2 N = 15 |
|---|---|---|
Median age at allo-HCT, years (range) | 42 (10–57) | 51 (4–60) |
Gender, n (%) | ||
 Male | 13 (39.4%) | 11 (73.3%) |
 Female | 20 (60.6%) | 4 (26.7%) |
Chromosome normal, n (%) | 23 (69.7%) | 9 (60.0%) |
FLT3-ITD mutation, n (%) | ||
 Yes | 10 (30.3%) | 0 |
 No | 23 (69.7%) | 15 (100%) |
NPM1 mutation, n (%) | 0 | 0 |
Risk category | ||
 Favorable | 0 | 0 |
 Intermediate | 33 | 15 |
 Adverse | 0 | 0 |
Median WT1 expression level at initial diagnosis | 25.25 (0.23-83.20) | 18.80 (1.40-53.50) |
No remission before transplant, n (%) | 2 (6.1%) | 1 (6.7%) |
Donor type, n (%) | ||
 HLA-matched sibling | 7(21.2%) | 5(33.3%) |
 Haploidentical | 26(78.8%) | 10(66.7%) |
ABO blood type match, n (%) | ||
 Compatible | 17 (51.5%) | 7 (46.7%) |
 Incompatible | 16 (48.5%) | 8 (53.3%) |
Conditioning regimen, n (%) | ||
 Chemotherapy based | 33 (100%) | 15 (100%) |
 TBI based | 0 | 0 |
Cell compositions in allografts | ||
 Median MNC, × 108/kg (range) | 7.82 (6.04-10.86) | 8.54 (6.10-10.86) |
 Median CD34+ count, × 106/kg (range) | 2.32 (0.27-6.67) | 1.89 (0.84-5.34) |
 Granulocyte engraftment time, day (range) | 13 (8-25) | 13 (11-19) |
 Platelet engraftment time, day (range) | 14 (10-74) | 13 (10-53) |
 II–IV°aGVHD | 8 (24.2%) | 1 (6.7%) |
 aGVHD | 18 (54.5%) | 4 (26.7%) |
 cGVHD | 5 (15.2%) | 5 (33.3%) |
DLI after transplant, n (%) | ||
 For relapse prevention | 2 (6.1%) | 0 |
 For intervention | 4 (12.1%) | 2 (13.3%) |
Prognosis, n (%) | ||
 Relapse | 6 (18.2%) | 0 |
 Treatment-related death | 7 (21.2%) | 2 (13.3%) |
 Relapse death | 6 (18.2%) | 0 |